A study of the relationship between the enzyme DDX5, liver cancer and sorafenib, published in the Nature journal Cell Death & Disease points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.
Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.
